Perindopril/amlodipine

Drug Profile

Perindopril/amlodipine

Alternative Names: Acerycal; Amlodipine/perindopril; Bi-Prestarium; Calcertil; Co-Prestarium; Coveram; Covercard; Covercor; Coverlam; Coversical; Coversyl AM; Perindopril arginine/amlodipine besylate; Prestalia; Prestance; Prestarium-Co; Presteram; Prexanor; Proacertil; Procoversyl; Reaptan; S-05985; Viacoram

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Servier
  • Developer Servier; Symplmed
  • Class Antihypertensives; Dihydropyridines; Indoles
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease; Hypertension

Most Recent Events

  • 24 Feb 2016 Symplmed Pharmaceuticals has patent protection for perindopril/amlodipine in USA
  • 29 Jan 2016 Registered for Hypertension (Treatment-naive) in Canada (PO)
  • 09 Jul 2015 Launched for Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top